Needham Reiterates Buy on Revolution Medicines, Maintains $57 Price Target

Benzinga · 05/08 12:02
Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $57 price target.